GAMMA Investing LLC Purchases 180,005 Shares of Exact Sciences Co. (NASDAQ:EXAS)

GAMMA Investing LLC lifted its position in Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 4,899.4% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 183,679 shares of the medical research company's stock after acquiring an additional 180,005 shares during the period. GAMMA Investing LLC owned about 0.10% of Exact Sciences worth $7,951,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. Capital World Investors lifted its holdings in shares of Exact Sciences by 10.7% during the 4th quarter. Capital World Investors now owns 17,537,617 shares of the medical research company's stock valued at $985,439,000 after buying an additional 1,696,321 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in Exact Sciences by 74.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,760,241 shares of the medical research company's stock valued at $323,669,000 after acquiring an additional 2,462,165 shares in the last quarter. T. Rowe Price Investment Management Inc. lifted its stake in Exact Sciences by 25.8% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 4,269,823 shares of the medical research company's stock valued at $239,922,000 after acquiring an additional 876,985 shares during the last quarter. Geode Capital Management LLC lifted its stake in Exact Sciences by 0.5% in the fourth quarter. Geode Capital Management LLC now owns 3,122,798 shares of the medical research company's stock valued at $175,165,000 after acquiring an additional 16,828 shares during the last quarter. Finally, Mackenzie Financial Corp grew its position in Exact Sciences by 107.7% in the fourth quarter. Mackenzie Financial Corp now owns 2,919,325 shares of the medical research company's stock worth $164,037,000 after acquiring an additional 1,513,873 shares in the last quarter. Institutional investors and hedge funds own 88.82% of the company's stock.

Analyst Upgrades and Downgrades

EXAS has been the topic of several recent research reports. Robert W. Baird raised their target price on Exact Sciences from $69.00 to $72.00 and gave the company an "outperform" rating in a report on Friday, May 2nd. Barclays raised their price objective on Exact Sciences from $55.00 to $75.00 and gave the company an "overweight" rating in a research note on Friday, May 2nd. Royal Bank of Canada boosted their target price on Exact Sciences from $52.00 to $54.00 and gave the stock a "sector perform" rating in a report on Friday, May 2nd. William Blair reaffirmed an "outperform" rating on shares of Exact Sciences in a research report on Thursday, February 20th. Finally, Scotiabank lifted their price target on shares of Exact Sciences from $70.00 to $73.00 and gave the company a "sector outperform" rating in a research report on Monday, February 24th. Two equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $70.90.

Exact Sciences Stock Performance

NASDAQ:EXAS traded up $1.55 on Tuesday, reaching $56.18. 3,750,388 shares of the company's stock were exchanged, compared to its average volume of 2,600,792. The firm has a market cap of $10.60 billion, a price-to-earnings ratio of -10.09 and a beta of 0.98. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.15 and a quick ratio of 1.93. The stock has a fifty day simple moving average of $50.03 and a 200-day simple moving average of $52.17. Exact Sciences Co. has a 52 week low of $39.97 and a 52 week high of $72.83.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical research company reported ($0.21) earnings per share for the quarter, beating analysts' consensus estimates of ($0.37) by $0.16. The business had revenue of $706.79 million during the quarter, compared to analyst estimates of $688.58 million. Exact Sciences had a negative return on equity of 5.29% and a negative net margin of 37.29%. The company's quarterly revenue was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.60) EPS. As a group, sell-side analysts predict that Exact Sciences Co. will post -0.58 earnings per share for the current year.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.